Jesse L Berry1,2, Liya Xu3, A Linn Murphree1,2, Subramanian Krishnan1, Kevin Stachelek1, Emily Zolfaghari1,2, Kathleen McGovern1, Thomas C Lee1,2, Anders Carlsson3, Peter Kuhn3,4,5,6, Jonathan W Kim1,2, David Cobrinik1,2,4,7,8, James Hicks3,4. 1. The Vision Center at Children's Hospital Los Angeles, Los Angeles, California. 2. USC Roski Eye Institute, Keck School of Medicine of USC, University of Southern California (USC), Los Angeles. 3. Department of Biological Sciences, USC Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles. 4. Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles. 5. Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles. 6. Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles. 7. Department of Biochemistry and Molecular Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles. 8. The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.
Abstract
Importance: Retinoblastoma (Rb) is one of the first tumors to have a known genetic etiology. However, because biopsy of this tumor is contraindicated, it has not been possible to define the effects of secondary genetic changes on the disease course. Objective: To investigate whether the aqueous humor (AH) of Rb eyes has sufficient tumor-derived DNA to perform genetic analysis of the tumor, including DNA copy number alterations. Design, Setting, and Participants: This investigation was a case series study at a tertiary care hospital (Children's Hospital Los Angeles) with a large Rb treatment center. Cell-free DNA (cfDNA) was isolated from 6 AH samples from 3 children with Rb, including 2 after primary enucleation and 1 undergoing multiple intravitreous injections of melphalan for vitreous seeding. Samples were taken between December 2014 and September 2015. Main Outcomes and Measures: Measurable levels of nucleic acids in the AH and identification of tumor-derived DNA copy number variation in the AH. The AH was analyzed for DNA, RNA, and micro-RNA using Qubit high-sensitivity kits. Cell-free DNA was isolated from the AH, and sequencing library protocols were optimized. Shallow whole-genome sequencing was performed on an Illumina platform, followed by genome-wide chromosomal copy number variation profiling to assess the presence of tumor DNA fractions in the AH cfDNA of the 3 patients. One child's cfDNA from the AH and tumor DNA were subjected to Sanger sequencing to isolate the RB1 mutation. Results: Six AH samples were obtained from 3 Rb eyes in 3 children (2 male and 1 female; diagnosed at ages 7, 20, and 28 months). A corroborative pattern between the chromosomal copy number variation profiles of the AH cfDNA and tumor-derived DNA from the enucleated samples was identified. In addition, a nonsense RB1 mutation (Lys→STOP) from 1 child was also identified from the AH samples obtained during intravitreous injection of melphalan, which matched the tumor sample postsecondary enucleation. Sanger sequencing of the AH cfDNA and tumor DNA with polymerase chain reaction primers targeting RB1 gene c.1075A demonstrated this same RB1 mutation. Conclusions and Relevance: In this study evaluating nucleic acids in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphalan, the results suggest that the AH can serve as a surrogate tumor biopsy when Rb tumor tissue is not available. This novel method will allow for analyses of tumor-derived DNA in Rb eyes undergoing salvage therapy that have not been enucleated.
Importance: Retinoblastoma (Rb) is one of the first tumors to have a known genetic etiology. However, because biopsy of this tumor is contraindicated, it has not been possible to define the effects of secondary genetic changes on the disease course. Objective: To investigate whether the aqueous humor (AH) of Rb eyes has sufficient tumor-derived DNA to perform genetic analysis of the tumor, including DNA copy number alterations. Design, Setting, and Participants: This investigation was a case series study at a tertiary care hospital (Children's Hospital Los Angeles) with a large Rb treatment center. Cell-free DNA (cfDNA) was isolated from 6 AH samples from 3 children with Rb, including 2 after primary enucleation and 1 undergoing multiple intravitreous injections of melphalan for vitreous seeding. Samples were taken between December 2014 and September 2015. Main Outcomes and Measures: Measurable levels of nucleic acids in the AH and identification of tumor-derived DNA copy number variation in the AH. The AH was analyzed for DNA, RNA, and micro-RNA using Qubit high-sensitivity kits. Cell-free DNA was isolated from the AH, and sequencing library protocols were optimized. Shallow whole-genome sequencing was performed on an Illumina platform, followed by genome-wide chromosomal copy number variation profiling to assess the presence of tumor DNA fractions in the AH cfDNA of the 3 patients. One child's cfDNA from the AH and tumor DNA were subjected to Sanger sequencing to isolate the RB1 mutation. Results: Six AH samples were obtained from 3 Rb eyes in 3 children (2 male and 1 female; diagnosed at ages 7, 20, and 28 months). A corroborative pattern between the chromosomal copy number variation profiles of the AH cfDNA and tumor-derived DNA from the enucleated samples was identified. In addition, a nonsense RB1 mutation (Lys→STOP) from 1 child was also identified from the AH samples obtained during intravitreous injection of melphalan, which matched the tumor sample postsecondary enucleation. Sanger sequencing of the AH cfDNA and tumor DNA with polymerase chain reaction primers targeting RB1 gene c.1075A demonstrated this same RB1 mutation. Conclusions and Relevance: In this study evaluating nucleic acids in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphalan, the results suggest that the AH can serve as a surrogate tumor biopsy when Rbtumor tissue is not available. This novel method will allow for analyses of tumor-derived DNA in Rb eyes undergoing salvage therapy that have not been enucleated.
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Tao Xie; Chunsheng Zhang; Bin Zhang; Cliona Molony; Asa Oudes; Chris Roberts; Hongyue Dai; Eric Schadt; John Lamb Journal: OMICS Date: 2010-02
Authors: Jesse L Berry; Liya Xu; Irsan Kooi; A Linn Murphree; Rishvanth K Prabakar; Mark Reid; Kevin Stachelek; Bao Han A Le; Lisa Welter; Bibiana J Reiser; Patricia Chévez-Barrios; Rima Jubran; Thomas C Lee; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks Journal: Mol Cancer Res Date: 2018-07-30 Impact factor: 5.852
Authors: Laura S Hiemcke-Jiwa; Ninette H Ten Dam-van Loon; Roos J Leguit; Stefan Nierkens; Jeannette Ossewaarde-van Norel; Joke H de Boer; Floor F Roholl; Roel A de Weger; Manon M H Huibers; Jolanda D F de Groot-Mijnes; Jonas J W Kuiper Journal: JAMA Ophthalmol Date: 2018-10-01 Impact factor: 7.389
Authors: Liya Xu; Ashley Polski; Rishvanth K Prabakar; Mark W Reid; Patricia Chevez-Barrios; Rima Jubran; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry Journal: Mol Cancer Res Date: 2020-05-20 Impact factor: 5.852
Authors: Jesse L Berry; Francis L Munier; Brenda L Gallie; Ashley Polski; Sona Shah; Carol L Shields; Dan S Gombos; Kathleen Ruchalski; Christina Stathopoulos; Rachana Shah; Rima Jubran; Jonathan W Kim; Prithvi Mruthyunjaya; Brian P Marr; Matthew W Wilson; Rachel C Brennan; Guillermo L Chantada; Murali M Chintagumpala; A Linn Murphree Journal: Pediatr Blood Cancer Date: 2021-02-23 Impact factor: 3.167
Authors: Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco Journal: J Cancer Res Clin Oncol Date: 2018-10-22 Impact factor: 4.553
Authors: Ashley Polski; Liya Xu; Rishvanth K Prabakar; Xiaowu Gai; Jonathan W Kim; Rachana Shah; Rima Jubran; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry Journal: Genes Chromosomes Cancer Date: 2020-06-09 Impact factor: 5.006
Authors: Liya Xu; Lishuang Shen; Ashley Polski; Rishvanth K Prabakar; Rachana Shah; Rima Jubran; Jonathan W Kim; Jacklyn Biegel; Peter Kuhn; David Cobrinik; James Hicks; Xiaowu Gai; Jesse L Berry Journal: Ophthalmic Genet Date: 2020-08-17 Impact factor: 1.803